Who Is the Appropriate RCC Patient to Receive Combination Ipilimumab/Nivolumab?

A roundtable discussion, moderated by Brian Rini, MD, of the Vanderbilt University Medical Center, focused on the spectrum of therapy for frontline renal cell carcinoma (RCC), including a comparison of monotherapy and doublet and triplet treatment options. Dr. Rini was joined by a panel that included Monty Pal, MD; Moshe Ornstein, MD; and Shuchi Gulati, MD, MSc. In the next segment of the roundtable series, the panel discusses which patients in their practices would be candidates for ipilimumab/nivolumab combination, including consideration of patient characteristics and a discussion of relevant study data.